Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement - Eriksson, BI; Borris, LC; Dahl, OE (Thromb Res, 2007)
et al.